BRPI0922870A8 - uso de ao menos um composto da fórmula i, do composto ohod ou seus derivados farmaceuticamente aceitáveis, do composto na-ohod, composição farmacêutica e/ou nutracêutica e método cosmético - Google Patents

uso de ao menos um composto da fórmula i, do composto ohod ou seus derivados farmaceuticamente aceitáveis, do composto na-ohod, composição farmacêutica e/ou nutracêutica e método cosmético

Info

Publication number
BRPI0922870A8
BRPI0922870A8 BRPI0922870A BRPI0922870A BRPI0922870A8 BR PI0922870 A8 BRPI0922870 A8 BR PI0922870A8 BR PI0922870 A BRPI0922870 A BR PI0922870A BR PI0922870 A BRPI0922870 A BR PI0922870A BR PI0922870 A8 BRPI0922870 A8 BR PI0922870A8
Authority
BR
Brazil
Prior art keywords
compound
ohod
pharmaceutical
formula
pharmaceutically acceptable
Prior art date
Application number
BRPI0922870A
Other languages
English (en)
Portuguese (pt)
Inventor
López Daniel
Ávila Martín Gerard
Barceló Coblijn Gwendolyn
Barceló Estarellas Juana
Taylor Green Julian
Vicente Ruiz Escribá Pablo
Álvarez Martínez Rafael
Teres Jiménez Silvia
Lladó Canellas Victoria
Busquets Xaubet Xavier
Original Assignee
Univ Illes Balears
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42242375&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0922870(A8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Illes Balears filed Critical Univ Illes Balears
Publication of BRPI0922870A2 publication Critical patent/BRPI0922870A2/pt
Publication of BRPI0922870A8 publication Critical patent/BRPI0922870A8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A23L33/12—Fatty acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L5/00—Preparation or treatment of foods or foodstuffs, in general; Food or foodstuffs obtained thereby; Materials therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/231—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having one or two double bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Nutrition Science (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Mycology (AREA)
  • Emergency Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • AIDS & HIV (AREA)
  • Child & Adolescent Psychology (AREA)
  • Psychiatry (AREA)
BRPI0922870A 2008-12-09 2009-12-04 uso de ao menos um composto da fórmula i, do composto ohod ou seus derivados farmaceuticamente aceitáveis, do composto na-ohod, composição farmacêutica e/ou nutracêutica e método cosmético BRPI0922870A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES200803480A ES2342997B1 (es) 2008-12-09 2008-12-09 Alpha derivados de acidos grasos cis-monoinsaturados para ser usados como medicamento.
PCT/ES2009/070561 WO2010066931A1 (es) 2008-12-09 2009-12-04 Alfa-derivados de ácidos grasos cis-monoinsaturados para ser usados como medicamento

Publications (2)

Publication Number Publication Date
BRPI0922870A2 BRPI0922870A2 (pt) 2016-01-12
BRPI0922870A8 true BRPI0922870A8 (pt) 2017-12-26

Family

ID=42242375

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0922870A BRPI0922870A8 (pt) 2008-12-09 2009-12-04 uso de ao menos um composto da fórmula i, do composto ohod ou seus derivados farmaceuticamente aceitáveis, do composto na-ohod, composição farmacêutica e/ou nutracêutica e método cosmético

Country Status (18)

Country Link
US (3) US9000042B2 (OSRAM)
EP (4) EP2842555B1 (OSRAM)
JP (2) JP5711140B2 (OSRAM)
KR (1) KR101683643B1 (OSRAM)
CN (1) CN102355897B (OSRAM)
AU (6) AU2009326993B2 (OSRAM)
BR (1) BRPI0922870A8 (OSRAM)
CA (1) CA2745052C (OSRAM)
DK (3) DK3366285T3 (OSRAM)
ES (5) ES2342997B1 (OSRAM)
HU (2) HUE037396T2 (OSRAM)
IL (1) IL213354A (OSRAM)
MX (1) MX2011005978A (OSRAM)
PL (3) PL2842556T3 (OSRAM)
PT (4) PT2842555T (OSRAM)
RU (1) RU2531353C2 (OSRAM)
SI (1) SI3366285T1 (OSRAM)
WO (1) WO2010066931A1 (OSRAM)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2342997B1 (es) 2008-12-09 2011-06-06 Universitat De Les Illes Balears Alpha derivados de acidos grasos cis-monoinsaturados para ser usados como medicamento.
WO2011089265A1 (en) * 2010-01-25 2011-07-28 Bridge Bioresearch Plc Use of fatty acid compounds for lowering blood glucose levels
ES2401629B1 (es) * 2011-10-07 2014-03-04 Universitat De Les Illes Balears Enantiómeros de 2-hidroxiderivados de ácidos grasos y su uso como medicamentos.
WO2013132092A1 (en) 2012-03-09 2013-09-12 Pensieve International Plc Use of monounsaturated fatty acid compounds for controlling the body weight of a dog or a cat
RU2679443C2 (ru) * 2014-10-21 2019-02-11 Университат Де Лес Ильес Балеарс Способ синтеза гидрокситриглицеридов и их применение для профилактики и лечения заболеваний
CA3082144A1 (en) * 2017-11-16 2019-05-23 The Research Foundation For The State University Of New York Use of 2-hydroxyoleic acid for the treatment of systemic lupus erythematosus and other immune pathologies
ES2911474B2 (es) * 2020-11-17 2023-02-06 Univ Illes Balears Profarmacos de acidos grasos monoinsaturados y sus metabolitos: usos medicos y como biomarcadores
CN115052852A (zh) * 2020-01-29 2022-09-13 巴利阿里群岛大学 α-羟基化脂肪酸代谢产物、其医学用途以及作为生物标志物的用途
US12440467B2 (en) * 2021-12-09 2025-10-14 The Florida International University Board Of Trustees Treatment and prevention of infections using vegetable oil-derived polyols

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4928172B1 (OSRAM) * 1969-10-27 1974-07-24
CH558321A (de) * 1971-08-03 1975-01-31 Ciba Geigy Ag Verfahren zur herstellung von carbonsaeuren bezw. carbonsaeuresalzen.
US3931306A (en) 1973-10-23 1976-01-06 International Flavors & Fragrances Inc. Process for producing isomer mixtures containing high proportions of cis-2-methyl-3-pentenoic acid
DE2448339A1 (de) * 1974-10-10 1976-04-22 Basf Ag Verfahren zur herstellung von olefinisch ungesaettigten carbonsaeureestern
DE2559201B2 (de) * 1975-12-30 1978-06-15 Hoechst Ag, 6000 Frankfurt Organozinnverbindungen und ihre Verwendung als Stabilisatoren
US4241097A (en) * 1979-09-13 1980-12-23 International Flavors & Fragrances Inc. Use of benzodionones in augmenting or enhancing the aroma and taste of a foodstuff
US4391757A (en) * 1981-11-27 1983-07-05 Carstab Corporation Organic antimony containing stabilizer compositions for halogenated polymers
JPS5899432A (ja) * 1981-12-09 1983-06-13 Maruzen Sekiyu Kagaku Kk 不飽和脂肪酸またはその塩およびそれからなる抗菌剤
US4551279A (en) 1984-01-09 1985-11-05 G. D. Searle & Co. Protease inhibitors
FR2609032B1 (fr) * 1986-12-30 1990-01-05 Centre Nat Rech Scient Epoxydes fonctionnels enantiomeriquement purs, leur procede de preparation et leur application comme synthons chiraux
US4808403A (en) * 1987-03-17 1989-02-28 International Flavors & Fragrances Inc. Use of N,N-diethyl-m-toluamide and/or the ethyl ester of 2-methyl-3-pentenoic acid as insect attractants
US5504107A (en) * 1990-01-12 1996-04-02 The Ohio State University Research Foundation Optically pure 4-alkenyl- or 4-alkanyl-2-hydroxytetronic acids and pharmaceutical use thereof
GB9003201D0 (en) * 1990-02-13 1990-04-11 Unilever Plc Cosmetic composition
US5208260A (en) * 1990-03-29 1993-05-04 G. D. Searle & Co. Vinyl Glycine derivatives for memory and learning enhancement or treatment of a cognitive disorder
US5198250A (en) 1990-07-16 1993-03-30 Lipotech Partners Limited Partnership Food and pharmaceutical compositions containing short chain monounsaturated fatty acids and methods of using
AU1926592A (en) * 1991-04-10 1992-11-17 Eugene J. Van Scott Compositions comprising 2-hydroxycarboxylic acids and related compounds, and methods for alleviating signs of dermatological aging
US6300373B1 (en) 1993-09-10 2001-10-09 American Biogenetic Sciences, Inc. Antiproliferative and neurotrophic molecules
JP3489703B2 (ja) * 1995-10-23 2004-01-26 株式会社ノエビア 微細エマルション組成物
US5856537A (en) * 1996-06-26 1999-01-05 The Scripps Research Institute Inhibitors of oleamide hydrolase
JPH10182338A (ja) * 1996-12-20 1998-07-07 Noevir Co Ltd 水中油型乳化組成物
EP1039902B1 (en) * 1997-11-24 2006-03-08 The Scripps Research Institute Inhibitors of gap junction communication
GB9926833D0 (en) * 1999-11-15 2000-01-12 Univ Sunderland Compositions
GB2385589A (en) * 2000-08-07 2003-08-27 Sofitech Nv Surfactant
ES2186576B1 (es) * 2001-10-11 2004-09-16 Universitat De Les Illes Balears Acido 2-hidroxioleico para utilizar como medicamento.
US6702756B2 (en) * 2001-12-11 2004-03-09 University Technologies International Inc. Method and apparatus for diagnosing neurological impairment
MXPA04006991A (es) 2002-01-22 2004-11-10 Syngenta Participations Ag Compuestos heterociclicos substituidos con fenilo, utiles como herbicidas.
US7462349B2 (en) * 2002-10-24 2008-12-09 Nurit Kalderon Beta interferon for the treatment of chronic spinal cord injury
US20040214215A1 (en) 2003-03-07 2004-10-28 Yu Ruey J. Bioavailability and improved delivery of alkaline pharmaceutical drugs
CN101947306B (zh) * 2003-05-15 2014-06-18 安皮奥制药股份有限公司 T-细胞介导的疾病的治疗
ES2229935B1 (es) * 2003-10-10 2006-10-01 Universitat De Les Illes Balears Utilizacion del acido hidroxioleico y compuestos analagos del mismo como aditivos alimentarios funcionales.
KR100756890B1 (ko) * 2005-08-19 2007-09-07 경희대학교 산학협력단 신경세포 보호활성을 갖는 올레산을 함유하는 조성물
JP2009051732A (ja) * 2005-12-13 2009-03-12 Meiji Seika Kaisha Ltd Ｐｐａｒリガンド活性を有する組成物
WO2009127009A1 (en) 2008-04-18 2009-10-22 Commonwealth Scientific And Industrial Research Organisation Condensation polymers
AU2009238222A1 (en) * 2008-04-18 2009-10-22 Commonwealth Scientific And Industrial Research Organisation Polyurethanes
ES2342997B1 (es) * 2008-12-09 2011-06-06 Universitat De Les Illes Balears Alpha derivados de acidos grasos cis-monoinsaturados para ser usados como medicamento.

Also Published As

Publication number Publication date
SI3366285T1 (sl) 2021-11-30
AU2019222955A1 (en) 2019-09-19
US20110294883A1 (en) 2011-12-01
EP2374453A4 (en) 2012-05-30
EP2842556A3 (en) 2015-08-05
AU2018229472A1 (en) 2018-10-04
CN102355897B (zh) 2014-06-04
JP2012511510A (ja) 2012-05-24
EP3366285A1 (en) 2018-08-29
ES2673406T3 (es) 2018-06-21
WO2010066931A1 (es) 2010-06-17
KR101683643B1 (ko) 2016-12-07
EP2842555A3 (en) 2015-04-15
PT2842555T (pt) 2018-07-06
JP5711140B2 (ja) 2015-04-30
PL3366285T3 (pl) 2022-01-10
PT2374453E (pt) 2015-04-28
PT2842556T (pt) 2018-03-19
CA2745052A1 (en) 2010-06-17
AU2009326993A1 (en) 2011-07-07
EP2842556B1 (en) 2018-01-31
EP2842556A2 (en) 2015-03-04
IL213354A (en) 2017-06-29
KR20110126100A (ko) 2011-11-22
EP2374453B1 (en) 2015-02-18
EP2842555A2 (en) 2015-03-04
ES2342997A1 (es) 2010-07-20
AU2009326993B2 (en) 2016-06-16
HUE037396T2 (hu) 2018-08-28
ES2535498T8 (es) 2016-08-19
RU2011128335A (ru) 2013-01-20
DK2842556T3 (en) 2018-03-26
US9730906B2 (en) 2017-08-15
CA2745052C (en) 2017-11-07
US20150297548A1 (en) 2015-10-22
ES2342997B1 (es) 2011-06-06
ES2535498T3 (es) 2015-05-12
JP2015061856A (ja) 2015-04-02
AU2016228171A1 (en) 2016-09-29
US20180193297A1 (en) 2018-07-12
CN102355897A (zh) 2012-02-15
PL2842556T3 (pl) 2018-07-31
AU2016228167A1 (en) 2016-09-29
EP2842555B1 (en) 2018-04-18
MX2011005978A (es) 2011-10-11
AU2018229474A1 (en) 2018-10-04
US10588883B2 (en) 2020-03-17
US9000042B2 (en) 2015-04-07
AU2018229474B2 (en) 2019-08-22
RU2531353C2 (ru) 2014-10-20
WO2010066931A4 (es) 2010-08-05
PT3366285T (pt) 2021-10-07
PL2374453T3 (pl) 2015-07-31
IL213354A0 (en) 2011-07-31
ES2899274T3 (es) 2022-03-10
EP2374453A1 (en) 2011-10-12
AU2018229472B2 (en) 2019-07-18
BRPI0922870A2 (pt) 2016-01-12
AU2019222955B2 (en) 2020-11-05
DK3366285T3 (da) 2021-10-04
DK2374453T3 (en) 2015-03-30
EP3366285B1 (en) 2021-06-30
ES2661412T3 (es) 2018-03-28
HUE056170T2 (hu) 2022-01-28

Similar Documents

Publication Publication Date Title
CY2024007I2 (el) Γλυκοπυρανοζυλο-υποκατεστημενα παραγωγα βενζονιτριλιου, φαρμακευτικες συνθεσεις που περιεχουν τετοιες ενωσεις, η χρηση τους και μεθοδοι παρασκευης τους
BRPI0922870A8 (pt) uso de ao menos um composto da fórmula i, do composto ohod ou seus derivados farmaceuticamente aceitáveis, do composto na-ohod, composição farmacêutica e/ou nutracêutica e método cosmético
BRPI0716633A2 (pt) compostos derivados de piridin-3-ila, composiÇço farmacÊutica e uso de um composto como agente imunomodulador
BR112012003842A2 (pt) composição farmacêutica, método de formulação e uso da mesma
BRPI0821115A2 (pt) Composto derivado de aminotriazol, medicamento, composição farmacêutica e uso do composto
BRPI0916235A2 (pt) composto, composição farmacêutica, uso do composto ou da composição, e, método para tratar um paciente infectado com hcv
BRPI1011876A2 (pt) "composição farmacêutica estável e métodos de uso da mesma"
BRPI0913726A2 (pt) rapalogs, composições farmacêuticas, métodos de preparo e uso dos mesmos
BRPI0910557A2 (pt) composições farmacêuticas de paclitaxel, análogos de paclitaxel ou conjugados de paclitaxel e métodos relacionados de preparação e uso.
BRPI0921699A2 (pt) complexo antioxidante, composicoes cosmeticas e farmaceutica contendo o referido complexo e uso deste complexo
BRPI0908021A2 (pt) Composto, composição farmacêutica, e, usos do composto ou da composição farmacêutica
BRPI1009324A2 (pt) compostos e/ou farmaceuticamente aceitáveis dos mesmos, composição farmacêutica e respectivos usos
BRPI0720124A2 (pt) Composições farmacêuticas e seus métodos de uso.
BRPI0809667A2 (pt) Composto, medicamento e composição farmacêutica que o contém e uso do composto
BRPI0912717A2 (pt) Composição farmacêutica, e, uso de 5-azacitidina
BRPI0915120A2 (pt) composto derivado de oxima, uso do referido composto e composição farmacêutica
BRPI0917001A2 (pt) composto, composição farmacêutica, e, uso de um composto ou uma composição farmacêutica
CR10229A (es) Derivados de 1,2,4,5,-tetrahidro-3h-benzazepinas, su procedimiento de preparación y las composiciones farmacéuticas que las contienen
BRPI1014865A2 (pt) "composição e formulação farmacêutica comreendendo derivados de nitrocatecol, e, método para fabricar uma composição ou formulação farmacêutica"
BRPI0918206A2 (pt) derivados de animoéster e composição medicinal destes
IL200153A (en) History of Ethnon, including and use of pharmaceutical preparations
BRPI1009392A2 (pt) "formulação farmacêutica, e, uso de uma quantidade farmaceuticamente eficaz de uma formulação farmacêutica."
BRPI0909296A2 (pt) uso de pelo menos um princípio ativo, e, composições cosmética, farmacêutica e/ou dermatológica
CR10665A (es) Nuevos derivados de diosmetina, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen
BRPI0821327A2 (pt) Derivado de catecol, composição farmacêutica contendo o mesmo, uso do derivado de catecol, e uso da composição farmacêutica

Legal Events

Date Code Title Description
B15K Others concerning applications: alteration of classification

Ipc: A61K 31/201 (2006.01), A23L 33/12 (2016.01), A61K

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06T Formal requirements before examination [chapter 6.20 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]